This updated 2025 guideline addresses critical topics including prevention of mother-to-child transmission and horizontal transmission, treatment in immune-tolerant and indeterminate phases (“grey zone”), treatment discontinuation, and hepatocellular carcinoma (HCC) surveillance.

Patients with cirrhosis face some of the highest surgical risks, and until now, guidance towards the approach to perioperative management has been fragmented and inconsistent. This new ACG clinical guideline consolidates the evidence into a structured roadmap comparing risk calculators, CSPH evaluation, and procedure-specific considerations.

Semaglutide for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis Paul Y. Kwo, MD, FACG  Professor of Medicine and Director of  Hepatology,…

The authors highlight the 2025 ACG Guideline on malnutrition and nutritional recommendations in liver disease, emphasizing early screening, individualized nutritional goals, and targeted supplementation to improve outcomes across various etiologies and stages of chronic liver disease.

This evidence-based summary examines a RCT which aimed to assess the efficacy of early antiviral treatment with tenofovir alafenamide in patients with non-cirrhotic chronic HBV and moderate to high viremia.

This summary reviews the challenges of FDA approval for obeticholic acid in an evidence-based review of the COBALT study.

Safety and Tolerability of Medications for Alcohol Use Disorder Nikki Duong, MD1 and Paul Y. Kwo, MD, FACG2 1Clinical Assistant…

Decreasing Cirrhosis Risk in MASLD: Don’t Drink Alcohol! Nicole E. Rich, MD, MSCS Assistant Professor, Associate Director of the Liver…

Tirzepatide Produces NASH Resolution and  Decreases Fibrosis: Results from the SYNERGY-NASH Trial Nicole E. Rich, MD MSCS Assistant Professor, Associate…

First FDA-Approved NASH Treatment Produces NASH Resolution and Decreases Fibrosis: Results From the Landmark Phase 3 MAESTRO-NASH Trial Phillip Leff,…